Escitalopram Oxalate
Product Images NDC 70934-163

6 FDA label images from Denton Pharma, Inc. Dba Northwind Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Escitalopram Oxalate (NDC 70934-163). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

70934 163 30 Master Bottle Label Approval Rev B 01 19

70934 163 30 Master Bottle Label Approval   Rev B 01 19
Label for Escitalopram Tablets USP 10mg by Denton Pharma, Inc. DBA Northwind Pharmaceuticals, containing 30 tablets. The label includes storage instructions, dosage note to see package insert, and warnings to keep out of reach of children. It indicates 'Rx Only' and specifies the product NDC as 70934-163-30.*
FDA Label Image

1 (A659eec9 07cf 4399 Abab 7e8036d8b6ad 01)

1 (A659eec9 07cf 4399 Abab 7e8036d8b6ad 01)
A data table showing treatment-emergent adverse reactions observed with escitalopram oxalate versus placebo for major depressive disorder. It lists various adverse reactions by system categories, with corresponding percentage incidences for escitalopram oxalate (N=715) and placebo (N=592). The table includes autonomic nervous system, nervous system, gastrointestinal, general, psychiatric, respiratory, and urogenital disorders.*
FDA Label Image

2 (A659eec9 07cf 4399 Abab 7e8036d8b6ad 02)

2 (A659eec9 07cf 4399 Abab 7e8036d8b6ad 02)
Table 3 displays treatment-emergent adverse reactions with a frequency of over 2% that are greater than placebo in patients treated for Generalized Anxiety Disorder. It compares adverse reactions for escitalopram oxalate (N=429) versus placebo (N=427) across categories including autonomic nervous system, central and peripheral nervous system, gastrointestinal, general, musculoskeletal, psychiatric, respiratory, and urogenital system disorders.*
FDA Label Image

1 (A659eec9 07cf 4399 Abab 7e8036d8b6ad 03)

1 (A659eec9 07cf 4399 Abab 7e8036d8b6ad 03)
Chemical structure of escitalopram oxalate showing its molecular arrangement with fluorophenyl and cyanophenyl groups and the oxalate salt indicated by C2H2O4.*
FDA Label Image

Logo (A659eec9 07cf 4399 Abab 7e8036d8b6ad 04)

FDA Label Image

1 (A659eec9 07cf 4399 Abab 7e8036d8b6ad 05)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.